EUVIMEDEUVIMED entdecken
EditorialKommentarOpen Access · CC BY 4.0

Reply: “Entering a new GALAXI: The importance of long-term data in Crohn’s disease clinical trials”

Anita Afzali iD, Rian Van Rampelbergh iD

Inflammatory Bowel Diseases · 01.07.2026 · 32 (7) · 1428-1429

DOI: 10.1093/ibd/izag082 ↗

Kurz gefasst

Editorial in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 15.05.2026. Verfasst von Anita Afzali und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, University of Cincinnati College of Medicine, Cincinnati, OH, United States. Die Arbeit nennt 4 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson & Johnson.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
  • Johnson & Johnson, Antwerp, Belgium.

ORCID-Profile: Anita Afzali, Rian Van Rampelbergh

Förderung

  • Johnson & Johnson

Zitieren

APA

Afzali, A., & Van Rampelbergh, R. (2026). Reply: “Entering a new GALAXI: The importance of long-term data in Crohn’s disease clinical trials”. Inflammatory Bowel Diseases, 32(7), 1428-1429. https://doi.org/10.1093/ibd/izag082

Vancouver

Afzali A, Van Rampelbergh R. Reply: “Entering a new GALAXI: The importance of long-term data in Crohn’s disease clinical trials”. Inflammatory Bowel Diseases. 2026;32(7):1428-1429. doi:10.1093/ibd/izag082

BibTeX
@article{Afzali2026,
  author = {Afzali, Anita and Van Rampelbergh, Rian},
  title = {Reply: “Entering a new GALAXI: The importance of long-term data in Crohn’s disease clinical trials”},
  journal = {Inflammatory Bowel Diseases},
  year = {2026},
  volume = {32},
  number = {7},
  pages = {1428--1429},
  doi = {10.1093/ibd/izag082}
}
Kostenlos starten →